46 Quarters of funding available means no further capital raisings for a decade

What I liked in the quarterly cash flow and activity report


*AstraZeneca/Starpharma confirmed its Phase 1 clinical trial AZD0466 DEP^® is going fall steam ahead and  the opening of addittonal sites  in the USA is on schedule

*Fleurstat BVgel now ranks as the #1 topical BV treatment in Australia. Metronidazole and Clindamycin both come in topical applications (Metronidazole 0.75% gel 5g, intravaginally Clindamycin 2% vaginal cream 5g)

*Dep Docetaxel, Dep Cabazitaxel, and Dep Irinotecan trials are progressing very well with further efficacy signals in all three trials

*Starpharma is currently finalising arrangements with potential partners prior to commencement of new Targeted (ADC) and non-ADC DEP^® programs, following successful meetings at the JP Morgan Healthcare Conference in San Francisco in January.

*Higher priority focusing on antiviral products (SPL 7013 viral conjunctivitis solution)

*Starpharma’s business operations continue to operate with minimal disruption

*The design of the DEP^® clinical programs is such that  COVID-19 is not expected to adversely affect the integrity of trial results.

*Currently there has been no disruption with supply of VivaGel^® BV to end users. The supply chain activities and key inventory levels remain adequate.

*Estimated quarters of funding available........43 (this is 10 + years worth of funds)!!!